Former President Trump is once again pushing for lower prescription drug prices, reportedly engaging in negotiations with Roche and Novartis as he seeks to leverage the issue ahead of the 2024 election. This effort builds upon previous attempts during his first term – including a 2020 executive order aiming for “Most Favored Nation” pricing [[1]] – and comes as the Biden administration also pursues drug price reforms. The potential agreements, which reportedly include an ultimatum to the companies, could reshape the pharmaceutical market and impact access to medications for American consumers.
Trump Reportedly Reaches Agreements with Roche, Novartis on Drug Pricing
Former U.S. President Donald Trump is reportedly nearing agreements with pharmaceutical giants Roche and Novartis regarding drug pricing, according to multiple media reports. The potential deals come as Trump seeks to address healthcare costs and potentially secure support ahead of the upcoming U.S. presidential election. The news has sparked interest among investors tracking the pharmaceutical sector and its ongoing relationship with U.S. policy.
Sources indicate that the U.S. administration is aiming to establish “Most Favored Nation” (MFN) agreements with several pharmaceutical companies, including AbbVie, in addition to Roche and Novartis. These agreements would tie the prices of certain drugs sold in the U.S. to the lowest prices offered in other developed countries.
Details of the agreements remain limited, but reports suggest Trump has issued an ultimatum to the companies. The potential for lower drug prices in the U.S. could significantly impact the revenue of these multinational corporations, while also offering potential relief to American consumers.
The Swiss pharmaceutical companies, Roche and Novartis, have been specifically mentioned in connection with the negotiations. The agreements could involve commitments from the companies to lower prices on specific medications sold in the United States.
The move follows previous attempts by the Trump administration to lower drug prices through executive action and legislation. The Biden administration has also pursued similar goals, but with a different approach. This latest development suggests a renewed focus on direct negotiations with pharmaceutical companies.
The potential agreements are still under development, and their final form and impact remain to be seen. Market analysts are closely watching the situation for further details and potential implications for the pharmaceutical industry and healthcare markets.
